Katharina S. Höffgen , Jennifer Dabel , Christian P. Konken , Dominic A. Depke , Sven Hermann , Wolfgang Dörner , Sonja Schelhaas , Michael Schäfers , Henning D. Mootz
{"title":"结合多表位 MoonTags 和标记纳米抗体,在体内细胞特异性 PET 成像中放大信号。","authors":"Katharina S. Höffgen , Jennifer Dabel , Christian P. Konken , Dominic A. Depke , Sven Hermann , Wolfgang Dörner , Sonja Schelhaas , Michael Schäfers , Henning D. Mootz","doi":"10.1016/j.nucmedbio.2024.108937","DOIUrl":null,"url":null,"abstract":"<div><p>Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and <em>in vitro</em> signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies <em>in vitro</em>. To test the poly-epitope approach <em>in vivo</em>, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; <em>p</em> < 0.01). <em>Ex vivo</em> gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (<em>p</em> < 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.</p></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"136 ","pages":"Article 108937"},"PeriodicalIF":3.6000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0969805124000635/pdfft?md5=538e2cf736ea2337611b25300b461524&pid=1-s2.0-S0969805124000635-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo\",\"authors\":\"Katharina S. Höffgen , Jennifer Dabel , Christian P. Konken , Dominic A. Depke , Sven Hermann , Wolfgang Dörner , Sonja Schelhaas , Michael Schäfers , Henning D. Mootz\",\"doi\":\"10.1016/j.nucmedbio.2024.108937\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and <em>in vitro</em> signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies <em>in vitro</em>. To test the poly-epitope approach <em>in vivo</em>, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [<sup>68</sup>Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; <em>p</em> < 0.01). <em>Ex vivo</em> gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (<em>p</em> < 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.</p></div>\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"136 \",\"pages\":\"Article 108937\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0969805124000635/pdfft?md5=538e2cf736ea2337611b25300b461524&pid=1-s2.0-S0969805124000635-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0969805124000635\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805124000635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
从基础研究到诊断,从单细胞到整个生物体,免疫认知为靶向成像技术奠定了坚实的基础。荧光或放射性同位素标记的抗体、抗体片段或纳米抗体可在结合后直接读出信号,实现从显微镜到全身成像的多功能成像。然而,由于信号强度与其表位结合的标记抗体数量直接相关(1:1 结合),低表达表位的灵敏度会限制可视化。我们首次开发了多表位标签,该标签具有多个短肽表位拷贝(1 至 7),特别是 MoonTag,可被标记的纳米抗体识别,旨在放大显微镜和细胞特异性 PET 成像中的信号。在瞬时转染的 HeLa 细胞或稳定转染的 A4573 细胞中,我们鉴定了复合物的形成和体外信号放大。事实上,使用荧光和放射性标记的纳米抗体,我们发现随着表位拷贝数的增加,体外信号放大近似线性。为了在体内测试多表位方法,我们将 A4573 肿瘤细胞皮下注射到 NSG 小鼠的肩部,一边是表达 7 个 MoonTags 的多表位 A4573 肿瘤细胞,另一边是 WT 细胞。我们使用[68Ga]标记的NODAGA结合MoonTag纳米抗体,在肿瘤植入后第8-9天进行了PET/CT成像。通过 PET 成像,我们在 7xMoonTag 肿瘤(1.7 ± 0.5%ID/mL)中观察到了[68Ga]标记的 NODAGA 连接的 MoonTag 纳米抗体的特异性结合,与 WT 肿瘤(1.1 ± 0.3%ID/mL; p
Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo
Immunorecognition provides an excellent basis for targeted imaging techniques covering a wide range from basic research to diagnostics and from single cells to whole organisms. Fluorescence- or radioisotope-labeled antibodies, antibody fragments or nanobodies enable a direct signal readout upon binding and allow for versatile imaging from microscopy to whole-body imaging. However, as the signal intensity directly correlates with the number of labeled antibodies bound to their epitopes (1:1 binding), sensitivity for low-expressing epitopes can be limiting for visualization. For the first time, we developed poly-epitope tags with multiple copies (1 to 7) of a short peptide epitope, specifically the MoonTag, that are recognized by a labeled nanobody and aimed at signal amplification in microscopy and cell-specific PET imaging. In transiently transfected HeLa cells or stably transduced A4573 cells we characterized complex formation and in vitro signal amplification. Indeed, using fluorescently and radioactively labeled nanobodies we found an approximately linear signal amplification with increasing numbers of epitope copies in vitro. To test the poly-epitope approach in vivo, A4573 tumor cells were injected subcutaneously into the shoulder of NSG mice, with A4573 tumor cells expressing a poly-epitope of 7 MoonTags on one side and WT cells on the other side. Using a [68Ga]-labeled NODAGA-conjugated MoonTag nanobody, we performed PET/CT imaging at day 8–9 after tumor implantation. Specific binding of a [68Ga]-labeled NODAGA-conjugated MoonTag nanobody was observed in 7xMoonTag tumors (1.7 ± 0.5%ID/mL) by PET imaging, showing significantly higher radiotracer accumulation compared to the WT tumors (1.1 ± 0.3%ID/mL; p < 0.01). Ex vivo gamma counter measurements confirmed significantly higher uptake in 7xMoonTag tumors compared to WT tumors (p < 0.001). In addition, MoonTag nanobody binding was detected by autoradiography which was spatially matched with histological analysis of the tumor tissues. In conclusion, we expect nanobody-based poly-epitope tag strategies to be widely applicable for multimodal imaging techniques given the advantageous properties of nanobodies and their amenability to genetic and chemical engineering.
期刊介绍:
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.